Valued at USD 1.18 Billion in 2025, the drug coated balloon catheter market is projected to reach USD 1.27 Billion in 2026 and USD 2.41 Billion by 2034, growing at a CAGR of 8.28% during the forecast period 2026–2034. North America was the largest regional market in 2025. Key players include Boston Scientific Corporation, Medtronic plc, B. Braun SE, Concept Medical Inc., Abbott, Koninklijke Philips N.V., Teleflex Incorporated, MicroPort Scientific Corporation, iVascular S.L.U., Meril Life Sciences Pvt. Ltd., Cordis, and Translumina Therapeutics. Drug-coated balloon catheters combine balloon angioplasty with localized drug delivery to reduce restenosis and improve blood flow. The report segments the market by product type, application, end-use industry and region.

Coronary DCB Leads the Drug Coated Balloon Catheter Market

The coronary DCB segment dominated in 2025, driven by the increasing prevalence of coronary artery disease and rising adoption of minimally invasive cardiac procedures. These devices are widely used in treating in-stent restenosis and small vessel diseases because they deliver anti-proliferative drugs without leaving a permanent implant, and a rising preference for stent-free interventions supports segment growth. The coronary DCB lead therefore mirrors the application-level dominance of coronary artery disease.

By application, coronary artery disease also dominated in 2025, reflecting the increasing burden of cardiovascular disease and growing numbers of angioplasty procedures worldwide. Drug-coated balloon catheters are increasingly preferred for complex coronary lesions and restenosis cases because they improve vessel patency and reduce repeat interventions. In the field of in-stent restenosis, Boston Scientific launched AGENT, designed to provide efficient drug delivery in complex anatomy.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/drug-coated-ballon-catheter-market

Peripheral DCB and the Fastest-Growing Application

The peripheral DCB segment is projected to grow at the fastest CAGR during the forecast period, owing to the rising incidence of peripheral artery disease and demand for effective vascular interventions. In 2024, the American College of Cardiology stated that peripheral artery disease affects 10–15% of the global population aged 50 and above, and 3–10% of adults in the western region.

Peripheral DCBs are increasingly used for femoropopliteal lesions to reduce restenosis rates, and growing adoption of advanced endovascular procedures supports expansion. The peripheral artery disease application is likewise projected to grow at the fastest CAGR, supported by the rising geriatric population and increasing prevalence of diabetes and smoking-related vascular disorders, along with growing awareness of minimally invasive treatment options and demand for improved blood flow restoration. Other applications covered include renal artery disease and biliary tract.

Disease Burden Shapes Regional Demand

The US Centers for Disease Control and Prevention reports about 805,000 heart attacks annually in the US, including 605,000 first-time and 200,000 recurrent cases, and 919,032 cardiovascular deaths in 2023. North America led in 2025 on high disease prevalence and strong adoption of vascular procedures. The US leads the region because of rising cardiovascular cases and high availability of advanced catheterization laboratories, and the presence of leading medical device manufacturers supports growth.

Asia Pacific is projected to grow at the fastest CAGR; CK Birla Hospitals reported in 2024 that India accounts for 20% of global heart attack deaths. Europe held the second-largest share, with the World Health Organization noting that cardiovascular diseases account for 42.5% of all deaths in the region. Germany, France and the United Kingdom show strong demand because of high adoption of interventional cardiology procedures, while Latin America and the Middle East & Africa are growing steadily on improving healthcare infrastructure.

Cost Economics and Clinical Risk

Drug Coated Balloon Catheter as pricing benchmarks place drug-coated balloons at USD 800–1,500 per device, between standard balloons at USD 200–400 and drug-eluting stents at USD 1,200–2,500. DCB angioplasty procedures cost USD 5,000–8,000 against USD 7,000–12,000 for stent placement, with hospitals benefiting from fewer repeat interventions, lower follow-up expenses, shorter stays and higher patient throughput.

Risks remain: restenosis, vessel dissection and inconsistent drug delivery in complex procedures, along with concerns about long-term efficacy and the demands of follow-up monitoring, can slow adoption.

More Trending Latest Reports By Polaris Market Research:

Gynecological Examination Chairs Market

Fluoropolymers Market

Safari Tourism Market

Enterprise Content Management Market

Automotive Ceramics Market

Mass Flow Controller Market

Hemophilia A Treatment Market

AI Trust, Risk and Security Management Market